Navigation Links
Cholesterol Drug Helps After Angioplasty

According to researchers at the Erasmus University Hospital, a common cholesterol fighting drug, a statin called Lescol or fluvastatin, can reduce the risk of heart complications by up to 20 percent for about 1 million American each year. "This reduction in major heart events -- such as dying of heart disease or suffering another heart attack is quite impressive," said Dr. Patrick Serruys,// professor of interventional cardiology at Erasmus University Hospital, Rotterdam, the Netherlands.

Serruys, the principal investigator of the Lescol Intervention Prevention Study or LIPS, and his colleagues recruited 1,022 patients from 55 institutions in Brazil, Canada and Europe who had undergone angioplasties to open clogged coronary arteries. Patients were eligible if they had their first angioplasty procedure within the previous six months.

In an angioplasty, a balloon-tipped catheter is guided by X-rays to the site of a main artery blockage that keeps blood from the heart. The balloon is inflated and crushes the blockage to the side of the artery wall to allow for greater blood flow. The correction rarely is permanent, however.

"More than a million Americans under angioplasty or similar procedures each year," Serruys said. "Although angioplasties are highly effective in the short-term, 2 out of every 5 patients will suffer a heart attack or will need to have bypass surgery or another angioplasty within five years."

In reporting the results of the LIPS trial at the annual meeting of the American College of Cardiology in Atlanta, Serruys said doctors gave patients a placebo or fluvastatin, a proven cholesterol-lowering medication. After about four years of treatment, Serruys found:

* A 22 percent reduction in death, heart attack or requiring another heart procedure, either open heart bypass surgery or another angioplasty.

* Diabetic patients on fluvastatin experienced a 47 percent reduction in the risk of havi ng a serious cardiac event.

* Patients with atherosclerosis or disease in more than one coronary artery who were taking fluvastatin experienced a 34 percent reduction in serious events.

* Patients who were on fluvastatin saw their low density lipoprotein or LDL -- the so-called bad cholesterol -- fall from about 131 milligrams per deciliter at the start of the trial to 99.1 mg/dL.

Dr. Ira Nash, associate director of the Cardiovascular Institute at Mt. Sinai School of Medicine, New York, said getting LDL cholesterol below 100 is one of the goals of the National Cholesterol Education Program. He also said treatment with cholesterol-lowering statin drugs has been shown to have additional benefits to patients aside from lowering cholesterol -- which is known to help reduce heart attack risk.

"This study may get the attention of the interventional cardiologist," said Dr. Roger Blumnethal, a spokesman for the American Heart Association and director of preventive cardiology at Johns Hopkins Univeristy, Baltimore, Md. "Often the interventionalist leaves the prescribing of statin medication to the primary care doctor and sometimes that addition to the patient's regimen falls through the cracks."

Interventional cardiologists most often perform angioplasties. "I think this and other new studies will go a long way in improving the quality of care of all patients with coronary artery disease," he said. Serruys said the researchers used the drug fluvastatin because it has a proven safety record as patients would be expected to continue taking the drugs for many years, possible for a lifetime. He said other statins, including more potent cholesterol-lowering agents, might not have as solid a safety record.

In LIPS, he said there were no indications of any worrisome liver abnormalities or muscle problems seen with other statin drugs. The study was supported by Novartis Pharmaceuticals, Basel, Switzerland, the manufac turer of Lescol.


'"/>




Related medicine news :

1. Low Cholesterol Linked to Severe Depression and Violent Behavior in Men
2. Eating More Often May Help Lower Cholesterol
3. Caution On Use of Cholesterol Drugs
4. High Cholesterol linked to Alzheimer’s diseas
5. Cholesterol lowering drugs increase neuropathy risk
6. Almonds Improve Cholesterol
7. Cholesterol-lowering therapy benefits older people also
8. Cholesterol lowering drugs aid people after heart transplant
9. New Cholesterol gene linked to Alzheimers
10. Children’s Cholesterol Matter
11. Tea Pill Lowers Cholesterol
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical Systems, Inc. ... the first company to offer robotic imaging to veterinary medicine is sponsoring the ... 941 for the American Association of Equine Practitioners 62nd Annual Convention from December ...
(Date:12/2/2016)... ... ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology that ... technology on the market can deliver all that rejiva can. , “Rejiva promotes relaxation ... health than the usual heart rate and steps taken”, adds Evens Augustin, CEO of ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is ... create versatile lower third titles with just a few clicks of the mouse," said ... includes 30 lower third animations. Choose from various styles with accented animations, rigid boxes, ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... needy individuals and families from eight different sites throughout Miami-Dade and Broward counties. ... 1,000 volunteers worked very hard on Thanksgiving morning by putting together individual meals ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: November 28, ... 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon Kleyne, America’s ... Global Climate Change and Your Health radio program syndicated on Voice of America, ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016   CytoSorbents Corporation (NASDAQ: ... its European Union approved CytoSorb ® cytokine adsorber ... patients worldwide, announced that Dr. Phillip Chan , ... Annual LD Micro Main Event investor conference held ... the Luxe Sunset Boulevard Hotel in Los ...
(Date:12/2/2016)... 2016  Today, Simpson Healthcare Executives, a global leader ... selected as winners of multiple awards at the 2016 ... the PLATINUM level, Blue Zones Menu at the GOLD ... Level, and our proprietary 3ConneX Platform at the HONORABLE ... we are excited to showcase our new Platinum and ...
(Date:12/2/2016)... The iShares Nasdaq Biotechnology Exchange-Traded Fund ... victory early in November. Less political risk has boosted ... predicting an uptick in M&A activities. Today, Stock-Callers.com takes ... they have fared at the last close: Celldex Therapeutics ... (NASDAQ: FOLD ), Navidea Biopharmaceuticals Inc. (NYSE ...
Breaking Medicine Technology: